In a clinically stable patient with chronic systolic heart failure on guideline‑directed medical therapy, when is cardiac PET myocardial perfusion/viability imaging indicated?

PET Myocardial Viability Imaging in Stable Chronic Systolic Heart Failure

In clinically stable patients with chronic systolic heart failure on guideline-directed medical therapy, PET myocardial perfusion/viability imaging is indicated when revascularization is being considered to identify hibernating myocardium that may recover function after revascularization, though recent evidence questions its ability to predict mortality benefit.

When to Order PET Viability Imaging

PET viability imaging should be considered in the following clinical scenario:

• Patient with ischemic cardiomyopathy (chronic systolic heart failure due to coronary artery disease)
• LVEF ≤35% with dysfunctional myocardial segments
• Revascularization is being contemplated (surgical or percutaneous)
• Goal is to identify hibernating myocardium that may regain function post-revascularization 1

The PET Viability Protocol

The standard protocol involves two components 1:

1. Rest myocardial perfusion imaging using 82-Rubidium, N-13 ammonia, or O-15 water
2. 18F-FDG metabolic imaging acquired 60-90 minutes after tracer injection to assess glucose uptake

Optional: Add pharmacological stress perfusion study to assess inducible ischemia 1

Interpretation Patterns

Four distinct patterns guide clinical decision-making 1:

• Mismatch pattern (reduced perfusion + preserved FDG uptake) = Hibernating myocardium - viable with potential for functional recovery
• Match pattern (reduced perfusion + reduced FDG uptake) = Scar tissue - non-viable, unlikely to recover
• Normal pattern (preserved perfusion + metabolism) = Healthy or stunned myocardium
• Reverse mismatch (normal perfusion + reduced metabolism) = May indicate non-ischemic cardiomyopathy

Quantitative thresholds for viability 1:

• Dysfunctional myocardium with rest perfusion >70% of remote myocardium AND FDG uptake >70% = viable
• Dysfunctional myocardium with mismatch pattern = viable
• Dysfunctional myocardium with stress-induced ischemia = viable

Critical Evidence Limitations

Major caveat: While PET has excellent technical performance (92% sensitivity, 63% specificity for predicting regional functional recovery 1), recent randomized trials challenge its clinical utility:

• The STICH trial showed no long-term prognostic benefit from viability-guided revascularization using SPECT and dobutamine stress echo 2
• The REVIVED-BCIS2 trial found that PCI plus optimal medical therapy did not reduce death or HF hospitalization compared to medical therapy alone in patients with viable myocardium (≥4 viable segments) 2
• A 2025 study using optimal [15O]H2O/[18F]FDG PET found it did not reliably predict LVEF improvement or survival after revascularization 3

Practical Clinical Algorithm

Step 1: Confirm ischemic etiology of heart failure (not non-ischemic cardiomyopathy)

Step 2: Assess if patient is a revascularization candidate based on:

• Coronary anatomy suitable for intervention
• Acceptable surgical/procedural risk
• Absence of prohibitive comorbidities

Step 3: If revascularization is feasible, consider PET viability imaging to:

• Quantify extent of hibernating myocardium (mismatch pattern)
• Identify predominantly scarred myocardium (match pattern) where revascularization unlikely to help

Step 4: Interpret results cautiously:

• ≥7% viable hibernating myocardium may suggest potential benefit from revascularization 4
• However, recognize that viability presence does not guarantee mortality benefit based on recent trials 2, 3
• Consider revascularization for symptom relief (angina, heart failure symptoms) rather than solely for mortality benefit

Advantages and Disadvantages

PET advantages over SPECT 1:

• Higher spatial resolution
• Differentiates scar from hibernating myocardium
• Superior attenuation correction (better for obese patients and females)

PET disadvantages 1:

• Limited availability
• High cost
• Radiation exposure (~11 mSv for combined perfusion and FDG protocols)

Alternative Imaging Modalities

Consider these alternatives when PET unavailable 1, 2:

• Cardiac MRI with late gadolinium enhancement - assesses transmural extent of scar
• Dobutamine stress echocardiography - identifies contractile reserve
• SPECT with thallium or 99mTc tracers - assesses perfusion and viability

Bottom Line for Clinical Practice

PET viability imaging has excellent technical accuracy for identifying hibernating myocardium but should not be the sole determinant for revascularization decisions in stable chronic systolic heart failure. The decision to revascularize should integrate clinical factors including symptom burden, coronary anatomy, surgical risk, and patient preferences, recognizing that recent randomized trials have not demonstrated mortality benefit from viability-guided revascularization strategies 2, 3. PET may be most useful when results would definitively change management—either confirming predominantly scarred myocardium (avoiding futile revascularization) or identifying extensive viable myocardium in symptomatic patients where functional improvement could enhance quality of life 4.